[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nut-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nut-carcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100459654","biology-of-young-lung-cancer-study-the-young-lung-study-100459654",false,"NCT05265429","Biology of Young Lung Cancer Study: The YOUNG LUNG Study","Inclusion Criteria:\n\n* Age 45 and under at lung cancer diagnosis\n* Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point\n* Provision of written informed consent\n* Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks\n* Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent\n\nExclusion Criteria:\n\n* Individuals who decline to sign consent\n* Individuals who are unable to give consent or assent and are without a designated healthcare proxy\n* Compromise of patient diagnosis or staging if tissue is used for research","ALL","15 Years",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.",[23,24,25],"Non Small Cell Lung Cancer","Small Cell Lung Carcinoma","NUT Carcinoma",[23,24,27,28,29],"Genetics","Genomics","Young lung cancer","RECRUITING","2025-10-28",{"date":33,"type":34},"2025-10-29","ACTUAL",{"date":36,"type":34},"2023-01-01",{"date":38,"type":19},"2027-08-01",{"name":40,"class":41},"Dana-Farber Cancer Institute","OTHER",4,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":55,"conditions":56,"keywords":70,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100598488","an-international-study-on-pediatric-patients-with-rare-tumors-100598488","NCT07072143","An International Study on Pediatric Patients With Rare Tumors.","The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.","PARTNER","Inclusion Criteria:\n\n* Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and\u002For treated in a participating country\u002Fcenter.\n* Written informed consent from the patient and\u002For the parent\u002Flegal guardian\n\nExclusion Criteria:\n\n* Absence of Written informed consent from the patient and\u002For the parent\u002Flegal guardian","0 Years","18 Years",{"count":54,"type":19},6250,"The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.",[57,58,59,60,61,62,63,64,25,65,66,67,68,69],"Paraganglioma\u002F Phaeochromocytoma","Melanoma and Other Malignant Neoplasms of Skin","Gastrointestinal Stromal Tumor (GIST)","Adrenocortical Tumor","Pancreatic Tumors","Esthesioneuroblastoma, Olfactory","Mesothelioma","Nasopharyngeal Carcinoma (NPC)","Pleuropulmonary Blastoma","Salivary Gland Tumors","Thymic Tumors","Thyroid Carcinoma","Appendiceal Cancers",[71,72,73,74,75],"children","rare tumors","very rare tumors","adolescents","PARTNER Study","2025-07-16",{"date":78,"type":34},"2025-07-18",{"date":80,"type":34},"2025-01-25",{"date":82,"type":19},"2049-06-06",{"name":84,"class":41},"Azienda Ospedaliera di Padova",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100476792","phase-1-dual-bet-and-cbpp300-inhibitor-in-patients-with-targeted-advanced-solid-tumors-and-hematological-malignancies-100476792","NCT05488548","Dual BET and CBP\u002Fp300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies","A Phase 1 Study of EP31670, a Dual BET and CBP\u002Fp300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies","Inclusion Criteria:\n\nPart 1\n\n* Relapse or refractory castration-resistant prostate cancer (CRPC) following at least one anti-androgen regimen and a docetaxel-containing regimen OR\n* metastatic or unresectable NUT midline carcinoma for which standard curative or palliative measures do not exist; OR\n\nPart 2\n\n* relapsed or refractory CMML following at least 4 cycles of hypomethylating agent-containing regimen or hydroxyurea unless demonstration of progression or intolerance;\n* advanced MF (intermediate or high-risk) following at least one JAK inhibitor-containing regimen or unsuitable candidates for JAK inhibitor treatments.\n\nPart 3: advanced MF (intermediate or high-risk) with ≤10% blasts in peripheral blood who have not achieved an adequate response or have lost the response to a JAK inhibitor-containing regimen after being on treatment for at least 3 months.\n\nPatients who have other types of relapsed or refractory solid tumors (Part 1) or hematological malignancies (Part 2) with pathological and\u002For biological features suggesting a potential benefit from dual BET and CBP\u002Fp300 inhibition may be enrolled after discussion with and approval from medical monitor and sponsor.\n\nEastern Cooperative Oncology Group (ECOG) performance status 0-1 Life expectancy ≥ 3 months Evaluable disease\n\nAdequate bone marrow function:\n\n* Hemoglobin ≥ 9.0 g\u002FdL (Part 1)\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FdL (Part 1)\n* Platelet count ≥100,000\u002FμL (Part 1) or ≥75,000\u002FμL (Part 3)\n\nAdequate renal function: Creatinine clearance (CLcr) ≥ 60 mL\u002Fmin\n\nAdequate liver function: total bilirubin ≤ 1.5 x ULN; alanine aminotransferase (ALT) or aspartate Aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN in patients with liver metastases\n\nInternal normalized ratio for prothrombin time (INR) ≤ 1.2 in patients not receiving chronic anticoagulation\n\nFour weeks from prior anti-cancer therapy including chemotherapy, immunotherapy, investigational anti-cancer therapy or 5 half-lives from targeted agents, radiation and have recovered from prior treatment toxicities to grade 1 or less.\n\nFour weeks from major surgery.\n\nFor fertile men and women, agreement to use effective contraceptive methods duration of study participation and 4 weeks after the last dose of study drug.\n\nAbility to understand and willingness to sign the informed consent form.\n\nExclusion Criteria:\n\n* New and progressive central nervous system (CNS) metastasis; patients with treated brain metastases are eligible if follow-up brain imaging at least 4 weeks after CNS-directed therapy shows no evidence of progression and the patient is neurologically stable\n* Corrected QT interval ≥470 msec\n* Uncontrolled concurrent illnesses including, but not limited to, ongoing active infection requiring intravenous antibiotics or antifungal agents, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness\u002Fsocial situations that would affect compliance with study requirements; patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of EP31670 are eligible for this trial\n* Pregnant or lactating women\n* Known history of hepatitis B, hepatitis C requiring antiviral treatment\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial",{"count":94,"type":19},75,"INTERVENTIONAL",[97],"PHASE1","A Phase 1, first-in-human study of EP31670, a dual BET and CBP\u002Fp300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies",[100,25,101,102],"Castrate Resistant Prostate Cancer","Chronic Myelomonocytic Leukemia","Myelofibrosis","2025-01-12",{"date":105,"type":34},"2025-01-14",{"date":107,"type":34},"2022-12-21",{"date":109,"type":19},"2025-05",{"name":111,"class":112},"Epigenetix, Inc.","INDUSTRY",6]